NCT04800900

Brief Summary

The presence of multimorbidities is very common among the elderly, which become major consumers of medicines. The process of prescribing medicines for the elderly should be done with caution, as the use of some medications may present more risks than benefits in this range age. Potentially inappropriate prescribing for the elderly has become a global concern for the promotion of an adequate pharmacotherapy, it becomes essential to be aware of the effectiveness and safety of medicines and the knowledge of which drugs whose risks of serious adverse reactions outweigh the benefit of your referral. In this sense, the present study has aim to evaluate the effectiveness of pharmaceutical interventions in frequency of omission of drugs with proven efficacy for cardiovascular diseases and promotion of treatment prescription inappropriate and polypharmacy. A prospective quasi experimental before and after study will be carried out in elderly patients diagnosed with cardiovascular disease admitted to the Ana Nery hospital, Salvador, Bahia, Brazil. A convenience sample will be collected, the data will be released and revised in a database built in the SPSS software and analyzed in the program statistic R and SPSS. At the end of the study, it is expected a decrease in the frequency of omission of medications and promotion of prescription drugs inappropriate.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
332

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

February 4, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 16, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2022

Completed
Last Updated

April 12, 2022

Status Verified

April 1, 2022

Enrollment Period

12 months

First QC Date

February 2, 2021

Last Update Submit

April 10, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effectiveness of pharmaceutical interventions measured by proportion of accepted interventions and all interventions

    The acceptance of all pharmaceutical interventions related to inappropriate prescribed drugs and omission of prescription during the hospitalization of the patient will be evaluated, through study completion, an average of 1 year

Secondary Outcomes (3)

  • Incidence of polypharmacy in elderly people with cardiovascular diseases measured by prescription containing five or more drugs

    First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year

  • Incidence of omission of prescription drugs with proven efficacy for cardiovascular diseases measured by the START criteria

    First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year

  • Incidence of potentially inappropriate drug prescription in elderly people with cardiovascular diseases measured by the Beers criteria

    First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year

Study Arms (1)

Pharmaceutical intervention

EXPERIMENTAL

A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors

Other: Pharmaceutical intervention

Interventions

A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs

Pharmaceutical intervention

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of cardiovascular disease
  • Discharge after 24 hours

You may not qualify if:

  • \* Death

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Ana Nery

Salvador, Estado de Bahia, 40301-155, Brazil

Location

Related Publications (2)

  • Gama RS, Passos LC, Amorim WW, Souza RM, Oliveira MG. Reducing Anticholinergic Burden in Hospitalised Older Adults: Analysis From the INFAR Study. Basic Clin Pharmacol Toxicol. 2026 Jan;138(1):e70160. doi: 10.1111/bcpt.70160.

  • Gama RS, Passos LC, Amorim WW, Souza RM, Oliveira MG. Effectiveness of Pharmacist Interventions in Improving Medication Use in Hospitalised Older Patients Diagnosed With Cardiovascular Diseases: INFAR Before-and-After Study. J Eval Clin Pract. 2025 Jun;31(4):e70190. doi: 10.1111/jep.70190.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor of Pharmacy and Evidence-based Health Care

Study Record Dates

First Submitted

February 2, 2021

First Posted

March 16, 2021

Study Start

February 4, 2021

Primary Completion

January 30, 2022

Study Completion

January 30, 2022

Last Updated

April 12, 2022

Record last verified: 2022-04

Locations